More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$95.24B
EPS
45.21
P/E ratio
18.4
Price to sales
4.95
Dividend yield
0.408%
Beta
0.098446
Previous close
$923.34
Today's open
$935.80
Day's range
$916.66 - $948.42
52 week range
$591.52 - $991.73
show more
CEO
Leonard S. Schleifer
Employees
15410
Headquarters
Tarrytown, NY
Exchange
Nasdaq Global Select
Shares outstanding
103447859
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Here's Why Regeneron (REGN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research • Nov 20, 2026

Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
Primary analysis from a potentially pivotal trial of Ordspono ® (odronextamab) in patients with R/R marginal zone lymphoma (MZL) to be shared in an oral presentation, part of a clinical development program evaluating Ordspono across a broad spectrum of lymphoma settings New data on Lynozyfic ® (linvoseltamab) in R/R systemic light chain (AL) amyloidosis also to be shared in an oral presentation, also part of a clinical development program evaluating Lynzoyfic across a broad spectrum of multiple myeloma settings and precursor conditions Additional presentations across a broad range of programs highlight next wave of innovation in blood disorders TARRYTOWN, N.Y., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its hematology portfolio and pipeline will be shared across 14 abstracts at the American Society of Hematology (ASH) 2026 Annual Meeting, taking place from December 12-15 in New Orleans.
GlobeNewsWire • Nov 19, 2026

REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis
Regeneron's Livsayis becomes the first and only siRNA therapy approved by the FDA for generalized myasthenia gravis, offering four subcutaneous doses a year.
Zacks Investment Research • Nov 19, 2026

2 Growth Stocks to Buy in November Without Any Hesitation
Vertex Pharmaceuticals' core business remains healthy, and it has a portfolio of kidney disease candidates that could top $10 billion in annual sales. Regeneron's Dupixent looks unstoppable, while a newer formulation of Eylea cushions the decline of the older version.
The Motley Fool • Nov 19, 2026

US FDA approves Regeneron's drug for generalized myasthenia gravis
US FDA approves Regeneron's drug for generalized myasthenia gravis
Reuters • Nov 18, 2026

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals
GlobeNewsWire • Nov 18, 2026

Regeneron Wins EC Clearance for Libtayo Dosing Flexibility
REGN gains EC approval for flexible Libtayo dosing across six cancer indications, potentially improving patient convenience and strengthening its oncology business.
Zacks Investment Research • Nov 18, 2026

Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approval
Regeneron Pharmaceuticals NASDAQ: REGN expects its three largest growth drivers to continue supporting revenue growth, while planning higher research and development spending and preparing for a specialty drug launch, executives said at the Jefferies Healthcare Conference.
MarketBeat • Nov 17, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications
Approval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeks Also approved is an option of reducing subsequent infusion times of Libtayo 350 mg by up to half, from 30 minutes to 15 minutes, after a well-tolerated 30-minute infusion TARRYTOWN, N.Y., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has approved an alternative, flexible dosing schedule for Libtayo® (cemiplimab) across all approved skin, lung and cervical cancer indications.
GlobeNewsWire • Nov 17, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Regeneron Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.